-Reuters
Related Posts
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $4.25 to $3.1.
Lexaria Incorporates New Subsidiary For CPG Products And Updates Human Nicotine Study
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under
Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2
The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.